Advanced Search

Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2009 August;50(4) > The Journal of Cardiovascular Surgery 2009 August;50(4):531-4

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUETHE JOURNAL OF CARDIOVASCULAR SURGERY

A Journal on Cardiac, Vascular and Thoracic Surgery

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632

Frequency: Bi-Monthly

ISSN 0021-9509

Online ISSN 1827-191X

 

The Journal of Cardiovascular Surgery 2009 August;50(4):531-4

VASCULAR SECTION 

    CASE REPORTS

Recombinant activated factor VII for treatment of refractory hemorrhage after surgery for acute aortic dissection

Grubitzsch H. 1, Vargas-Hein O. 2, Von Heymann C. 2, Konertz W. 1

1 Department of Cardiovascular Surgery University of Clinic Charité Campus Charité Mitte, Berlin, Germany
2 Department of Anaesthesiology and Intensive Care Medicine University Clinic Charité Campus Charité Mitte, Berlin, Germany

Despite appropriate treatment, surgery for aortic dissection is frequently associated with bleeding problems. In these series we report on the employment of recombinant activated factor VII (rFVIIa) for refractory hemorrhage after emergency surgery for acute type A aortic dissection, used to face the problems of postoperative blood loss and transfusion requirements. Despite the good results of the therapy, a patient presented with thrombosis of the left cavernous sinus. Although a risk of thromboembolic complications has to be considered, rFVIIa is a reasonable rescue option in life-threatening hemorrhage and enlarges our hemostatic armamentarium in surgery for acute aortic dissection.

language: English


FULL TEXT  REPRINTS

top of page